Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dexamethasone + Idasanutlin + Ixazomib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Idasanutlin | RO-5503781|RO 5503781|RO5503781|RG7388|RG-7388 | MDM2 Inhibitor 23 | Idasanutlin (RG7388) binds to MDM2 to block subsequent interaction with p53, which prevents degradation of p53, thereby resulting in restoration of wild-type p53 activity and potentially promoting apoptosis of tumor cells (PMID: 23808545, PMID: 32338053, PMID: 32020437). | |
Ixazomib | Ninlaro | MLN9708 | Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02633059 | Phase Ib/II | Dexamethasone + Idasanutlin + Ixazomib | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Completed | USA | 0 |